GENFIT Launches a Phase 2 Trial Evaluating Elafibranor

GENFIT Launches a Phase 2 Trial Evaluating Elafibranor on Hepatic Lipid Composition for NAFL

• Study objective to determine the effect of elafibranor, a dual PPAR alpha/delta agonist, on fatty acid saturation
• Phase 2 study to evaluate the effect of a 6-week, once daily treatment of elafibranor (120mg) vs. placebo on hepatic lipid composition in patients with Nonalcoholic Fatty Liver (NAFL)
• State of the art non invasive techniques (H-MRS) to be used to provide indications on both quantitative and qualitative evolution of liver fat